The Transition to Industry Biology in the Private Sector.

Slides:



Advertisements
Similar presentations
Gakava L Roche Products Ltd., Welwyn, UK
Advertisements

David M. Pollock Medical College of Georgia Discovery-Academia.
CONTRACT RESEARCH SERVICES 1537 NW 65th Avenue Plantation, FL USA Phone: (954) Fax: (954)
Research & Innovation Evolution from IMI1 to IMI2: challenges ahead Elmar Nimmesgern, PhD DG Research & Innovation 1.
1 Heather Davis September 27, 2011 Ottawa, Canada Biotech to Big Pharma Personal Experience.
Alternative Careers in Pharma and Biotechnology Douglas Buckley Ph.D. May 13, 2011 Alternative Career Symposium Baylor College of Medicine.
Michel Goldman, Executive Director Innovative Medicines Initiative (IMI)
1 February 15, 2006 Global Forum: Building Science, Technology and Innovation Capacity for Sustainable Growth and Poverty Reduction Prof. Bonnie Patterson.
ACCELERATING CLINICAL AND TRANSLATIONAL RESEARCH Anantha Shekhar MD, PhD Indiana University School of Medicine Indiana Clinical and.
EDC PHARMA SERVICES Capacity. Expertise. Solutions. Technology.
Medical Diagnostics NIAID Funding Opportunities Maria Y. Giovanni, Ph.D. Assistant Director for Microbial Genomics and Advanced Technologies National Institute.
S TRUCTURAL B IOINFORMATICS. A subset of Bioinformatics concerned with the of biological structures - proteins, DNA, RNA, ligands etc. It is the first.
Nanotechnology in Drug Discovery- Development and Delivery
Challenges in Clinical Applications for Nanotechnology N. Tony Eissa, MD Table 3.
January 3, 2003 Kevin Rakin President and Chief Executive Officer Kevin Rakin President and Chief Executive Officer Economic Summit and Outlook 2003.
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
The Health Care Sector Analysts: Heather Hund and Emily Butler.
UNIT 3.04 Career Opportunities By PresenterMedia.comPresenterMedia.com.
1 The UK Opportunity: what is experimental medicine? UNLOCK YOUR GLOBAL BUSINESS POTENTIAL Pre- clinical develop- ment Phase I Phase II Phase III Product.
Working in the Biotech/Pharmaceutical Industry October 11, 2007 Irene Griff, Ph.D. Program Manager Johns Hopkins Medical School Baltimore, MD.
Clinical Research Training
Target Institute of Medical Education & Research (TIMER) Provides Clinical Research services to Pharmaceutical, Biotechnology product companies right.
Chapter 1.3.  Sell 1 group of similar products.  Ex. The protocols for manufacturing recombinant human growth hormone are almost identical to those.
Public Private collaborations to optimise translational research and pathways to patients: IMI Magda Chlebus, Director Science Policy Warsaw, 22 May 2015.
Drugs Drugs & Medicine Emma Mackenzie December 19 th 2012 IB 12.
The Innovative Medicines Initiative (IMI) High level the IMI Concept, Strategic Research Agenda and Call topics Eva Lindgren.
WHAT IS OSHA The Occupational Safety and Health Administration.
Global Recognition of the Indian Biotech Sector - The Road Ahead Sept 26,2003 Hyderabad.
The Innovative Medicines Initiative A winning case for Joint Technology Initiative Status.
MEDICAL experts INDUSTRY Some of our clients. Pharmaceutical companies, manufacturers of medical and surgical devices, clinical research organizations,
THE BIOTECHNOLOGY WORKPLACE. OVERVIEW Biotechnology workplaces Laboratories.
PUTTING THE PATIENT AT THE CENTER OF HEALTHCARE RESEARCH Towards a more inclusive model.
The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.
Biotechnology and Schools: What’s the Connection?.
Careers Science and Engineering Information Provided By: Georgia Statewide Area Health Education Center (AHEC) PowerPoint.
Career Development Ruotao Wang 2012 – 06. For Happiness Career development is important part of your life! Staff working in the Pharmaceutical Industry.
Health Care Systems Delivering Health Care to the Community.
Warm-up While working at the Rest Haven Rehab Center, you walk into Mrs. Jones room to help her prepare for supper. Mrs. Jones is lying in the bed with.
Hamish Hawthorn ATP Innovations Australian Technology Park Sydney, Australia Angel Investing in Australia.
1 Trends in drug development programs in the era of Personalized Medicine Gunnar Saeter, M.D., Ph.D. Head, Institute for Cancer Research Oslo University.
Aarkstore - Sutent (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Category : Pharmaceuticals and Healthcare.
Interviewing for the Pharmaceutical Industry: what does it involve and how to succeed? David P Brooks.
BioFund Egor Gulyaev Investment Manager, MBA May,
1 Promotion in Management and Research Tracks in Industry Magdalena Alonso-Galicia, PhD Cardiovascular Diseases Department Merck Research Laboratories.
Grand Challenge Slide Toolkit THIS POWERPOINT INCLUDES A SELECTION OF SLIDES FOR YOU TO CHOOSE FROM WHEN TALKING ABOUT GRAND CHALLENGE – Summary slide.
1 Communicating with Venture Capitalists to Fund Your Research Raising Venture Capita l Michael Jirousek, Ph.D. Senior Advisor, Innovation Support Center.
© Coherent market Insights. All Rights Reserved BIOSIMILAR PIPELINE ANALYSIS MARKET Global Industry Insights, Trends, Outlook, and Opportunity Analysis,
Developing and Broadening Specialists in Research & Development
I am in the Biotechnology industry
Biotechnology R&D.
Clinical Research Contribution towards improving Clinical Care
Drug Discovery &Development
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
Industry Perspective: Expanded Access Programs
Translational Research: Case of Istanbul University
ATOM Accelerating Therapeutics for Opportunities in Medicine
Action: BM0806 Recent Advances in Histamine Receptor H4R Research
Gestora brasileiro focada exclusivamente na área da saúde.
Monoclonal Antibodies Market Forecast, Market Size - Ken Research.
Stefan Gijssels, Janssen Pharmaceutica
Sangers Sequencing Service Market is Witnessing High Growth by 2025
From Bench to Clinical Applications: Money Talks
Private sector involvement IPM-Tibotec case study
MONOJO Biotech Services Centre.
MONOJO Biotech Services Centre.
Opportunity Knocks… (Should I Answer?)
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
Cancer is a Challenge Cancer is common in humans – a public health problem ~1 of every 3 women will develop cancer ~1 of every 2 men will develop cancer.
Target disease and target populations for 21st century vaccine developmentIncluded in the list are the agents of infectious diseases for which vaccines.
Pharmaceuticals Industry
Presentation transcript:

The Transition to Industry Biology in the Private Sector

Topics: Types of Private-sector Positions for Biologists Key Differences Between Academia/Private Sector Different workplaces and job types in Pharmaceutical/Biotechnology Companies Research Areas Important Website But, can you go home again?

Jobs in the Private Sector 1.The Pharmaceutical and Biotech Industries. The Quest for Therapeutics. Many Companies Have Research Programs as Rigorous as Found in Academia. 2.Contract Research Laboratories (For-profit and Non-profit). “Science for Hire.” Work is Very Specific, Task-oriented.

Key Differences from Academia Tenure You Work as Part of a Team “Freedom” of Research Pursuits Hiring: Academia- Research Program Private Sector – Meet Immediate Need

Pharmaceutical/Biotech Industries (What’s Your Adrenaline Level?) Small StartupCompaniesLarger Established Companies Fewer People – Wear Many Hats Excitement for Company’s Mission Risky – Can be Lucrative or “Live Fast, Die Young Leave a Beautiful Corpse.” More Stable. Infrastructure in Place. Not as Diverse People Interactions as Startups Capital for Equipment More Available.

Some Key Therapeutic Targets Cancer – So much more is known now than >500 potential therapeutics in clinical trials. Mortality rates overall not greatly changed. Infectious Diseases – Microbial Mutation = Never- ending Battle. Clues from sequencing studies for new targets. Neurodegenerative Diseases – Alzheimer's (5 million in US currently), ALS, Parkinson's, etc. Immune Disorders/Inflammatory Diseases – Autoimmune diseases, Asthma. No new Lupus therapeutic in 30 years.

Two Major “Camps” in Pharma/Biotech DRUG DISCOVERY Basic Research for Efficacy Mechanism of Action Studies Technological Advances (Mouse Models, Sequencing, Mass Spec) Make It a Very Exciting Time in Discovery DRUG DEVELOPMENT Later Stage, When Therapeutic Looks Promising Safety Testing (Toxicology) Highly Regulated Science (GLPs - Must have SOPs, Validated Methods, Evidence of Equipment Calibration and Personnel Training.)

Get Familiar with Biospace.com:

Can You Return to Academia? Yes…But You Must Be Able to Publish!

Summary Exciting Time for Biotechnology Fulfillment of Bringing Therapeutics to Patients Roller Coaster or Merry-go-round? Ready to Put the Team First? Consider a Postdoc Position in Industry. Biospace.com Return to Academia? Make Sure You Can Publish.